Skip to main content
ASSEMBLY BIOSCIENCES, INC. logo

ASSEMBLY BIOSCIENCES, INC. — Investor Relations & Filings

Ticker · ASMB ISIN · US0453962070 LEI · 5299007Y1X8RBDFT8C40 US Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2026-06-05 Declaration of Voting R…
Country US United States of America
Listing US ASMB

About ASSEMBLY BIOSCIENCES, INC.

https://www.assemblybio.com/

Assembly Biosciences, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, small molecule antiviral therapeutics. The company leverages its deep expertise in virology to create innovative treatments for serious viral diseases, with a pipeline focused on conditions such as herpesviruses and chronic hepatitis B virus (HBV). Through strategic collaborations, including a partnership with Gilead Sciences, Assembly Biosciences aims to advance next-generation therapies designed to change the treatment paradigm for patients with viral infections.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 91% confidence The document is a U.S. SEC Form 8-K current report that primarily discloses the results of proposals submitted to a vote of the company’s stockholders at its annual meeting (Item 5.07), including director elections, advisory votes, ratification of auditors, and plan amendments. This precisely matches the definition of a Declaration of Voting Results filing (DVA).
2026-06-05 English
8-K
Capital/Financing Update Classification · 91% confidence The document is a Form 8-K “Current Report” under the Securities Exchange Act, disclosing the entry into an underwriting agreement for a registered offering of common stock and pre-funded warrants, net proceeds, underwriting terms, and attachments of the definitive transaction documents. It details a financing transaction and capital structure change (issuance of equity and warrants). This fits the Capital/Financing Update category.
2026-05-26 English
424B5
Share Issue/Capital Change Classification · 84% confidence The document is a prospectus supplement filed under SEC Rule 424(b)(5) detailing an offering of new shares of common stock and pre-funded warrants. It is not an earnings release, management report, or meeting material, but rather a formal announcement of a new capital raising transaction involving issuance of new equity and warrants. This aligns with the “Share Issue/Capital Change” category.
2026-05-22 English
424B5
Capital/Financing Update Classification · 90% confidence The document is a preliminary prospectus supplement filed pursuant to SEC Rule 424(b)(5) describing an underwritten offering of common stock and pre-funded warrants – essentially a financing prospectus for a securities issuance. It is not a periodic report (10-K, 10-Q), earnings release, management change notice, or proxy. Instead it details new share issuance and fundraising terms, fitting the Capital/Financing Update category.
2026-05-22 English
8-K
Regulatory Filings Classification · 91% confidence The document is a Form 8-K Current Report filed under the Securities Exchange Act, providing disclosures about a press release (Regulation FD Disclosure) and other event information. It does not contain financial statements, earnings data, dividends, share issues, management changes, or other specific events that map to a more precise category. As a generic regulatory filing, it falls under the fallback category Regulatory Filings (RNS).
2026-05-22 English
EFFECT - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
Regulatory Filings
2026-03-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.